Psychotropic polypharmacy is common in clinical practice although supporting evidence is limited. Extrapyramidal syndromes (EPS) are adverse events associated with use of psychotropic drugs, especially antipsychotics. There are quite a few reports that suggest association between each psychotropic drug and EPS; however, the risk of EPS associated with their polypharmacy has not been fully evaluated. This study aimed at examining the influence of psychotropic polypharmacy on EPS occurrence by drug category (anxiolytics, hypnotics, antidepressants, and antipsychotics).
Methods:
Sequence symmetry analyses were conducted using a large-scale Japanese health insurance claims database. This method assessed asymmetry in the distribution of EPS occurrence defined as both a diagnosis of EPS and a prescription for antiparkinsonian drugs before and after initiation of psychotropic drugs. The adjusted sequence ratio (ASR) and its 95% confidence interval (CI) were calculated.
Results:
All categories of psychotropic drugs (anxiolytics, hypnotics, antidepressants, and antipsychotics) were significantly associated with EPS, and the tendency was stronger in polypharmacy associated with them. A clearer association between polypharmacy of BZs and EPS was indicated. In the analyses by subclasses of drugs, BZs, tetracyclic antidepressants, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, typical and atypical antipsychotics were significantly associated with EPS. The ASR of atypical antipsychotics (ASR 11.3, 95% CI 7.95-16.4) was higher than that of typical ones (ASR 2.96, 95% CI 2.06-4.33).
Conclusions:
The association between psychotropic polypharmacy and EPS was indicated. Further investigation is needed to confirm these findings because of the pharmacoepidemiologic nature of this study.
LindenMLecrubierYBellantuonoCBenkertOKiselySSimonG. The prescribing of psychotropic drugs by primary care physicians: an international collaborative study. J Clin Psychopharmacol. 1999;19:132–140.
2.
MojtabaiROlfsonM. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67:26–36.
3.
NørgaardAJensen-DahmCGasseCHansenESWaldemarG. Psychotropic polypharmacy in patients with dementia: prevalence and predictors. J Alzheimers Dis. 2017;56:707–716.
4.
BrettJDanielsBKarangesEA. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. Br J Clin Pharmacol. 2017;83:2581–2588.
5.
KishimotoT. Psychotropic medication polypharmacy: a selective review of the world trend and predictors [in Japanese]. Jpn J Clin Psychiatry. 2013;42:159–167.
6.
National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council and State Medicaid Directors. Technical report on psychiatric polypharmacy. https://www.nasmhpd.org/sites/default/files/Polypharmacy.pdf. Published 2001. Accessed September 10, 2018.
7.
MooreTABuchananRWBuckleyPF. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68:1751–1762.
8.
GallingBRoldánAHagiK. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017;16:77–89.
9.
InadaK. Problem of polypharmacy [in Japanese]. Modern Physician. 2014;34:665–668.
10.
WestawayKSluggettJKAldermanCProcterNRougheadE. Prevalence of multiple antipsychotic use and associated adverse effects in Australians with mental illness. Int J Evid Based Healthc. 2016;14:104–112.
LehmanAFLiebermanJADixonLB. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2)(suppl):1–56.
14.
DayaluPChouKL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother. 2008;9:1451–1462.
15.
HaddadPMDasAKeyhaniSChaudhryIB. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol. 2012;26:15–26.
16.
RochonPAStukelTASykoraK. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165:1882–1888.
17.
DivacNProstranMJakovcevskiICerovacN. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;656370.
18.
MossmanD. A decision analysis approach to neuroleptic dosing: insights from a mathematical model. J Clin Psychiatry. 1997;58:66–73.
19.
InagakiATomitaM. Novel antipsychotics, antipsychotic polypharmacy and high-dose treatment in Japan [in Japanese]. Jpn J Clin Psychopharmacol. 2003;6:391–401.
20.
GillHSDeVaneCLRischSC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol. 1997;17:377–389.
21.
GerberPELyndLD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998;32:692–698.
22.
SchillevoortIvan PuijenbroekEPde BoerARoosRAJansenPALeufkensHG. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol. 2002;17:75–79.
23.
MadhusoodananSAlexeenkoLSandersRBrennerR. Extrapyramidal symptoms associated with antidepressants—a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry. 2010;22:148–156.
24.
ChenLYungWH. GABAergic neurotransmission in globus pallidus and its involvement in neurologic disorders. Sheng Li Xue Bao. 2004;56:427–435.
25.
PrommerEE. Midazolam-induced extrapyramidal side effects. J Pain Symptom Manage. 2008;36:e5–e6.
26.
HallasJ. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7:478–484.
27.
TsiropoulosIAndersenMHallasJ. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf. 2009;18:483–491.
28.
NakamuraK. Diagnosis procedure combination database would develop nationwide clinical research in Japan. Circ J. 2016;80:2289–2290.
29.
Ministry of Education Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare. Ethical Guidelines for Epidemiological Research. http://www.niph.go.jp/wadai/ekigakurinri/guidelines.pdf. Published 2002. Accessed September 10, 2018.
30.
MorrisJAGardnerMJ. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed). 1988;296:1313–1316.
31.
TakeuchiYKajiyamaKIshiguroCUyamaY. Atypical antipsychotics and the risk of hyperlipidemia: a sequence symmetry analysis. Drug Saf. 2015;38:641–650.
32.
LaiECPrattNHsiehCY. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol. 2017;32:567–582.
Analysis Section, Safety Division I, Pharmaceuticals and Medical Devices Agency. Report on a validation study using hospital information system data [in Japanese]. https://www.pmda.go.jp/files/000204444.pdf. Published 2014. Accessed September 10, 2018.
36.
TakadaMFujimotoMHosomiK. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther. 2014;52:181–191.
37.
HosomiK. Association of antipsychotic use with extrapyramidal symptoms: data mining of the Japanese national insurance claims database [in Japanese]. Jpn J Pharm Health Care Sci. 2016;42:87–97.
38.
GarrisonSRDormuthCRMorrowRLCarneyGAKhanKM. Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis. Arch Intern Med. 2012;172:120–126.
39.
InagakiAInadaT. Dose equivalence of psychotropic drugs. Part XX: dose equivalence of injectable antipsychotics [in Japanese]. Jpn J Clin Psychopharmacol. 2007;10:2373–2377.
40.
InagakiAInadaT. Dose equivalence of psychotropic drugs. Part XXI: dose equivalence of novel antipsychotics: blonanserin [in Japanese]. Jpn J Clin Psychopharmacol. 2008;11:887–890.
41.
InagakiAInadaT. Dose equivalence of psychotropic drugs. Part XXII: dose equivalence of depot antipsychotics III: risperidone long-acting injection [in Japanese]. Jpn J Clin Psychopharmacol. 2010;13:1349–1353.
42.
InagakiAInadaT. Dose equivalence of psychotropic drugs. Part XXV: dose equivalence of depot antipsychotics IV: aripiprazole once-monthly [in Japanese]. Jpn J Clin Psychopharmacol. 2015;18:1475–1480.
43.
InagakiAInadaT. Dose equivalence of psychotropic drugs. Part XXVI: dose equivalence of novel antipsychotics: asenapine [in Japanese]. Jpn J Clin Psychopharmacol. 2017;20:89–97.
44.
BrownDJMcArthurDMoulsdaleH. Subcutaneous midazolam as a cause of extrapyramidal side effects in a patient with prostate cancer. J Pain Symptom Manage. 2007;34:111–113.
45.
BattagliaJ. Pharmacological management of acute agitation. Drugs. 2005;65:1207–1222.
46.
MarderSR. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry. 2006;67(suppl 10):13–21.
47.
ZamanHSampsonSJBeckALS. Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev. 2017;12:CD003079.
48.
CarvalhoAFSharmaMSBrunoniARVietaEFavaGA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 2016;85:270–288.
49.
MeltzerHYYoungMMetzJFangVSSchyvePMAroraRC. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm. 1979;45:165–175.
50.
GuoMYEtminanMProcyshynRM. Association of antidepressant use with drug-related extrapyramidal symptoms: a pharmacoepidemiological sudy. J Clin Psychopharmacol. 2018;38:349–356.
51.
AraiM. Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran. J Neurol Neurosurg Psychiatry. 2003;74:137–138.
52.
MuraokaTOkuESugatakaKYamadaS. A case of severe parkinsonism associated with short-term treatment with milnacipran. Clin Neuropharmacol. 2008;31:299–300.
53.
DeuschleMMaseEZinkM. Dyskinesia during treatment with duloxetine. Pharmacopsychiatry. 2006;39:237–238.
54.
CeylanMEEvrenselA. Venlafaxine induced akathisia: a case report. Trends Psychiatry Psychother. 2016;38:117.
55.
GirishchandraBGJohnsonLCrespRMOrrKG. Mirtazapine-induced akathisia. Med J Aust. 2002;176:242.
AggarwalAKhandelwalAGargAJilohaRC. Akathisia associated with mianserin. J Clin Psychopharmacol. 2010;30:338–339.
58.
HawthorneJMCaleyCF. Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother. 2015;49:1136–1152.
59.
CaroffSNMannSCCampbellECSullivanKA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002;63(suppl 4):12–19.
60.
GebhardtSHärtlingFHankeM. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur Child Adolesc Psychiatry. 2006;15:371–382.
61.
MillerDDCaroffSNDavisSM. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008;193:279–288.
62.
CorrellCU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47:9–20.
63.
LeuchtSWahlbeckKHamannJKisslingW. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581–1589.
64.
LeuchtSCorvesCArbterDEngelRRLiCDavisJM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41.
65.
BurgyoneKAduriKAnanthJParameswaranS. The use of antiparkinsonian agents in the management of drug-induced extrapyramidal symptoms. Curr Pharm Des. 2004;10:2239–2248.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
